The Peptide CommonsEst. May 2024
Independent. We sell nothing and are affiliated with no manufacturer or pharmacy. Every moderation action is logged in public
Evidence · Trials · continued

Interim analyses and stopping rules — does this still hold? posts 31–35

This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1 · go to the accepted answer.

RR
r.restrepoTL24 Jul 2025#31

A treatment-policy estimand asks what happens to people assigned to a strategy, including those who abandon it. A hypothetical estimand asks what would have happened had everyone continued. Both are legitimate and they give different numbers.

It is worth stating the boring hypothesis before the interesting one.

18 likes 13mo
ML
m.lindqvistTL24 Jul 2025#32

Absolute and relative effects answer different questions. Write down the event rate in each arm and the difference between them; everything quotable is derived from those two numbers.

Somebody will have a better source than mine, and I hope they post it.

8 likes 13mo
NN
n.nybergTL24 Jul 2025 · edited#33
glossary_desk, post #10: Checked the Interim analyses and stopping rules claim against the primary source this morning. It survives, with a narrower scope than the version quoted here. Posting the narrower scope. Go to post

Post #31 describes the usual case. This is about the unusual one.

I would be cautious about generalising from the Interim analyses and stopping rules example above. It is a good example. It is one example.

0 likes in reply to #10 13mo
CL
c.lundgrenTL25 Jul 2025#34

Adding the measurement that post #31 says would settle it.

Practical experience of Interim analyses and stopping rules, offered as one case with the conditions stated, not as a general finding. Conditions first, because they are what make it interpretable.

0 likes 13mo
CF
c.falkTL25 Jul 2025#35

Absolute numbers, not just relative: a 30% relative reduction tells you the ratio but not the practical magnitude. The event rate in each arm and the difference between them tells you how many people benefit.

13 likes 13mo

Suggested topics

TopicParticipantsRepliesViewsActivity
What a statistical analysis plan adds that the paper does not
What a statistical analysis plan adds that the paper does not — that is the question, and I have not found it answered plainly anywhere I have looked. Statistical analysis plan, and specifically the version…
AAZLHE 2 6.6k 10h
Reading a trial's population section before its results — does this still hold?
Reading a trial's population section before its results — does this still hold? I have a specific reason for asking rather than idle curiosity, and the context is below. Reading STEP 1 ( N Engl J Med , 2021)…
TDEKVIREM+140 154 5.4k 14mo
Comparators chosen for regulatory reasons rather than clinical ones
On the subject in the title: Comparators chosen for regulatory reasons rather than clinical ones Working notes rather than a conclusion. An honest uncertainty about comparators chosen for regulatory reasons…
PESZTD 2 27k 14mo
Subgroup analyses: pre-specified versus discovered
Subgroup analyses: pre-specified versus discovered — setting out what I have, and where I think it stops being reliable. I would like to disagree carefully with the settled view on subgroup analyses, and I…
JHAEI 2 27k 1d
Run-in periods and the population they select — the long version
Run-in periods and the population they select — the long version Writing it up because I had to work it out twice and would rather nobody else did. A narrow question about Run-in periods, deliberately narrow,…
ALFREK 2 8.9k 4mo

Related topics — sharing the tags estimand, discontinuation & dropout, open label

TopicParticipantsRepliesViewsActivity
Amylin analogue mechanism: satiety signalling separate from GLP-1
Amylin analogue mechanism: satiety signalling separate from GLP-1 — setting out what I have, and where I think it stops being reliable. Trying to work out what would count as evidence on amylin analogue…
SRBIHIPINO+128 142 38k 13mo
Journal club: STEP 1 and the treatment-policy estimand — does this still hold?
Asking directly, because I could not find a straight answer: Journal club: STEP 1 and the treatment-policy estimand — does this still hold? Working notes on STEP 1 rather than a conclusion. I would rather…
MDAWRMJDVR+118 132 12k 15mo
Reading a combination trial: attributing effect to components
On the subject in the title: Reading a combination trial: attributing effect to components Working notes rather than a conclusion. Collecting what is known about reading a combination trial in one place,…
VMAHTTSVP 4 19k 11mo
Amylin and gastric emptying: overlapping mechanisms with incretins
On the subject in the title: Amylin and gastric emptying: overlapping mechanisms with incretins Working notes rather than a conclusion. Posting a small dataset on amylin and gastric emptying. It is mine, it…
TNLKA 2 50k 17mo
Why a glucagon receptor agonist in a weight-loss compound is not a contradiction — one year on
Why a glucagon receptor agonist in a weight-loss compound is not a contradiction — one year on — that is the question, and I have not found it answered plainly anywhere I have looked. The question about…
EHSBBOARB+3 7 1k 2mo